Insider Buying: Lipocine (NASDAQ:LPCN) Director Purchases 40,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $81,200.00. Following the acquisition, the director directly owned 203,797 shares of the company’s stock, valued at $413,707.91. This trade represents a 24.42% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Lipocine Stock Up 3.1%

LPCN stock traded up $0.06 on Tuesday, reaching $2.00. 1,692,305 shares of the company’s stock were exchanged, compared to its average volume of 305,426. The firm has a market cap of $14.60 million, a PE ratio of -1.19 and a beta of 1.09. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37. The stock has a fifty day moving average of $7.93 and a 200-day moving average of $5.77.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.26. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Key Headlines Impacting Lipocine

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Company insiders increased stakes — CEO Mahesh Patel bought 25,000 shares (~$2.03 avg) and director John W. Higuchi bought 123,000 shares, signaling insider confidence and providing buy-side support to the stock. Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
• Neutral Sentiment: HC Wainwright updated models upward — the firm raised FY2026 and quarterly EPS forecasts (e.g., FY2026 to ($1.91) from ($2.27) and several quarter EPS revisions) but keeps a “Neutral” rating, an outcome that reduces downside in estimates but does not convert to an upgrade. MarketBeat summary of analyst estimates
• Neutral Sentiment: Recent quarterly results showed a revenue beat and narrower-than-expected EPS loss (reported ($0.34) vs consensus ($0.60)), which supports the revised analyst estimates but the company remains loss-making and small-cap volatility is high. MarketBeat financial summary
• Negative Sentiment: HC Wainwright appears to have reduced its stance in a separate report (MSN coverage) — any downgrade or more cautious wording from a specialist biotech/healthcare desk can prompt short-term selling in a low-float name like LPCN. HC Wainwright & Co. downgrades Lipocine (LPCN)
• Negative Sentiment: Shareholder litigation inquiry — Johnson Fistel announced an investigation into potential claims involving Lipocine executives; legal risk and potential costs can weigh on sentiment and valuation. Johnson Fistel investigation announcement

Analysts Set New Price Targets

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a report on Monday. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.00.

Institutional Trading of Lipocine

A number of large investors have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new stake in shares of Lipocine during the fourth quarter valued at $1,602,000. Squadron Capital Management LLC acquired a new stake in shares of Lipocine during the fourth quarter valued at $4,256,000. Boothbay Fund Management LLC acquired a new stake in shares of Lipocine during the fourth quarter valued at $441,000. Diadema Partners LP acquired a new stake in shares of Lipocine during the fourth quarter valued at $2,095,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Lipocine during the fourth quarter valued at $567,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.